Follicular lymphoma and multiple myeloma treatment now available to Australians through $48m PBS listing
Monday, 01 October 2018
The Leukaemia Foundation welcomes the Federal Government’s announcement confirming new medicine for both follicular lymphoma and multiple myeloma will be added to Pharmaceutical Benefits Scheme (PBS) from 1 October 2018.
Leukaemia Foundation CEO Bill Petch said the PBS listing of Gazyva (obinutuzumab) would benefit around 700 people
Lymphoma and myeloma treatments to be subsidised through $48m PBS listing
The Leukaemia Foundation has applauded the Federal Government’s recent announcement of funding $48 million towards more affordable drugs for Australians living with blood cancer.
Leukaemia Foundation CEO Bill Petch said the Pharmaceutical Benefits Scheme (PBS) listing of Gazyva (obinutuzumab) this October
Unprecedented funds for cutting-edge research into myeloma
Australian researchers will share in $10 million of funding toward developing groundbreaking treatments to help people living with rare cancers and diseases, including myeloma.
The funding will be shared across six clinical trials and will be conducted by researchers at Monash
Australians urged to seek support this World Lymphoma Awareness Day
Friday, 14 September 2018
Australians living with lymphoma are surviving more but experiencing a fear of relapse, anxiety, depression and isolation according to a recent report.
And despite survival rates jumping from just 52 per cent in the early 1980s to 76 per cent today, those diagnosed in regional Australia are
Leukaemia Foundation continues to fight for Australians living with blood cancer
Friday, 07 September 2018
September is Blood Cancer Awareness Month
Every day another 35 Australians are diagnosed with a blood cancer or disorder, and according to the latest analysis from the Leukaemia Foundation, this number continues to rise. Leukaemia, lymphoma and myeloma and the blood disorder myelodysplastic syndrome (MDS) are four
New Multi-Million Dollar Research Program Announced As Light The Night Campaign Launches Today
Monday, 20 August 2018
The Leukaemia Foundation will today unveil the first project to receive funding from its new multi-million dollar national research program.
The Centre for Blood Transplant and Cell Therapy (CBTCT) will receive $1 million from the Leukaemia Foundation to meet the urgent need for new approaches to better
New class of anti-cancer drugs put cancers to permanent sleep
Thursday, 02 August 2018
Today, researchers from the Walter and Eliza Hall Institute (WEHI) announced that they have discovered a new class of anti-cancer drugs that can put cancer cells into permanent sleep, without the harmful side-effects caused by conventional cancer therapies such as chemotherapy.
This medical breakthrough, a world’s first,
EFFORTS UNDERWAY TO INCLUDE BLOOD CANCER IN THE AUSTRALIAN GENOMIC CANCER MEDICINE PROGRAM
Monday, 23 July 2018
The Leukaemia Foundation welcomes the Federal Government’s $50 million funding of The Australian Genomic Cancer Medicine Program that will see some of Australia’s sickest patients accessing potentially life-saving medical treatment.
The Leukaemia Foundation’s CEO, Bill Petch, said, “This is yet another good initiative by the Federal Government
Leukaemia Foundation supports Federal Government’s $250 million cancer package
Sunday, 15 July 2018
The Leukaemia Foundation is today welcoming the news of the unrestricted benefits listing announcement of the blood cancer drug Pegasys® (pegylated interferon alfa-2a) for Australians living with Myeloproliferative neoplasms (MPNs).
The support follows the $250 million announcement today by Health Minister Greg Hunt to subsidise four life-changing
Leukaemia Foundation officially launches new home base in WA
Friday, 13 July 2018
Australians diagnosed with a blood cancer such as leukaemia, lymphoma or myeloma, will now be able to stay at the Leukaemia Foundation’s brand new purpose-designed self-contained accommodation units located in Stirling Cross, close to Perth treatment centres and Leukaemia Foundation services.
It’s the first time all of